Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma

BACKGROUND: Antitumor immune response of programmed cell death ligand (PD-L1) has shown clinical value not only in Hodgkin lymphoma and EBV-associated lymphomas but also in EBV-negative diffuse large B cell lymphoma (DLBCL) of non-germinal center B cell-like (non-GCB) subtype. Signal transducer and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Hyun Jung, Yang, Jeong Mi, Lee, Jeong-Ok, Lee, Jong Seok, Paik, Jin Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245852/
https://www.ncbi.nlm.nih.gov/pubmed/30458835
http://dx.doi.org/10.1186/s12967-018-1689-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245852/
https://www.ncbi.nlm.nih.gov/pubmed/30458835
http://dx.doi.org/10.1186/s12967-018-1689-y

Ejemplares similares